← Russell 3000 cross-section

LQDA Liquidia Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$6.3bn
Revenue TTM
$451m
Net income TTM
$139m
Free cash flow
$151m
Composite score
60.8
Sector rank
#937

Valuation

P / E
45.6
EV / EBITDA
35.4
EV / sales
13.4
FCF yield
2.39%
Earnings yield vs 10-yr
-2.54pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
30.7%
EBITDA margin
37.8%
ROE
71.0%
ROIC
Revenue growth
2,233.7%

Insider activity, last 90 days

Net open-market
$-140.29m
Buyers
0
Sellers
13

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

One customer accounted for 100 % of service revenue, net. During the quarter ended June 30, 2026, adjustments to estimated provisions related to prior period sales were less than one percent of our total revenues for the quarter then ended. The components and calculation of basic and diluted net income (loss) per share are as follows: ​ ​ Due to their anti-dilutive effect, the calculation of diluted net income (loss) per share excludes the following common stock equivalent shares: ​ ​ Certain common stock warrants are included in the calculation of basic and diluted net income (loss) per share since their exercise price is de minimis. …Liquidia Corp, 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →